Home  /  Resource Library  /  MRD growth decelerated with venetoclax combined with either rituximab or obinutuzumab in patients with R/R CLL

MRD growth decelerated with venetoclax combined with either rituximab or obinutuzumab in patients with R/R CLL

Article discusses 2 clinical trials investigating venetoclax combined with obinutuzumab or rituximab for treatment of relapsed chronic lymphocytic leukemia.